In MS, EBI2 was shown to modulate the migration of CD4+ T cells in patients receiving natalizumab therapy [8] and in the EAE model, the influx of autoreactive lymphocytes into the CNS [7,18]. Here, GPR183 is linked to myeloid sarcoma.